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Abstract
Background Prognostic markers for meningioma recurrence are needed to guide patient management. Apart from rare hereditary
syndromes, the impact of a previous unrelated tumor disease on meningioma recurrence has not been described before.
Methods We retrospectively searched our database for patients with meningiomaWHO grade I and complete resection provided
between 2002 and 2016. Demographical, clinical, pathological, and outcome data were recorded. The following covariates were
included in the statistical model: age, sex, clinical history of unrelated tumor disease, and localization (skull base vs. convexity).
Particular interest was paid to the patients’ past medical history. The study endpoint was date of tumor recurrence on imaging.
Prognostic factors were obtained from multivariate proportional hazards models.
Results Out of 976 meningioma patients diagnosed with a meningiomaWHO grade I, 416 patients fulfilled our inclusion criteria.
We encountered 305 women and 111 men with a median age of 57 years (range: 21–89 years). Forty-six patients suffered from a
tumor other than meningioma, and no TERTmutation was detected in these patients. There were no differences between patients
with and without a positive oncological history in terms of age, tumor localization, or mitotic cell count. Clinical history of prior
tumors other than meningioma showed the strongest association with meningioma recurrence (p = 0.004, HR = 3.113, CI =
1.431–6.771) both on uni- and multivariate analysis.
Conclusion Past medical history of tumors other than meningioma might be associated with an increased risk of meningioma
recurrence. A detailed pre-surgical history might help to identify patients at risk for early recurrence.
Keywords Meningioma .WHO grade I . Prognostic factor . TERT promoter status . Unrelated tumor disease
Introduction
Meningiomas are the most common primary intracranial tu-
mors in adults. Annual incidence rate is estimated at 7.9 cases
per 100,000 persons, and prevalence appears to rise with age
[17]. Meningiomas are classified histologically according to
the WHO into grade I–III. The most important factors associ-
ated with tumor recurrence and survival are WHO grade but
also extent of surgical resection [4, 9, 11, 15, 16]. However,
20% of WHO grade I meningiomas recur after complete re-
section, illustrating an urgent need for further risk stratifica-
tion models [9]. More recent studies have also shown an as-
sociation of molecular profiles with meningioma recurrence
and progression, e.g., TERT (telomerase reverse transcriptase)
promoter mutation, DNA methylation profile, or loss of his-
tone H3K27me3 [3, 20, 21]. For patients with meningioma
WHO grade I and complete resection, markers prognostic of
potential tumor recurrence are urgently needed to guide pa-
tient management during follow-up.
The overwhelming majority of meningiomas are consid-
ered to be sporadic. However, factors such as past medical
history of tumors other than meningioma (including glioma,
acute lymphocytic leukemia, prostate cancer, papillary carci-
noma of the thyroid, uterus myomas, and endometriosis) but
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also cranial irradiation or hereditary cancer syndromes like
neurofibromatosis types 1 and 2, Turner’s syndrome, and
Werner’s syndrome may predispose for meningioma forma-
tion [2, 5, 7, 12, 13, 24, 28]. Similarly, within vestibular
schwannomas, a shortened time to progression was observed
within patients harboring an unrelated tumor disease [27].
Taken together, these findings already point to possible sys-
temic genetic and molecular factors that play a putative role in
the development of meningiomas but also in their recurrent
growths.
In the present study, we describe a large cohort of histolog-
ically verified and molecularly well-defined meningiomas
WHO grade I treated at a large academic cancer center with
complete resection.
We thoroughly analyzed patient’s clinical characteristics,
histopathological details, treatment strategies, and outcome




The study was approved by the ethics committee of Ludwig-
Maximilians University in Munich, Germany (approval num-
ber: 18-837). We retrospectively searched our institutional
database for patients with histologically verified intracranial
meningioma WHO grade I operated on between 2002 and
2016. Indications of surgical resection were symptomatic le-
sions, asymptomatic lesions with radiological documented tu-
mor progression, or patients preferred wish to be operated
upon an asymptomatic lesion without evidence of growth.
Patients with a follow-up time of less than 6 months were
excluded. For patients in which complete microsurgical resec-
tion as defined by Simpson grade I–III was provided, a com-
prehensive clinical and pathological chart review was per-
formed. Further stratification into Simpson grades was not
performed because results from our group showed poor sig-
nificance of intraoperative estimation of the extent of resec-
tion. In contrast, postoperative imaging methods such as MRI
or supplementary DOTATATE PET-CT scans showed a sig-
nificantly higher reliability in the assessment of a tumor rem-
nant [26]. Records were searched for demographics and clin-
ical findings particularly including past medical history, neu-
ropathological data, therapy, and outcome. Patients with
known hereditary cancer syndromes (e.g., neurofibromatosis
type 2) or multiple meningiomas were excluded from the
study. We limited our analysis on a single solid indicator
lesion. Date of death, date of last follow-up, and date of recur-
rence were obtained from charts filled during follow-up visits
to our outpatient clinic. Recurrence-free survival was calcu-
lated as interval from first diagnosis of meningioma WHO
grade I (set as date of surgical meningioma resection) until
radiological recurrence. Radiological recurrence was defined
as new contrast enhancement on postoperative MRI imaging
obtained earliest 3 months after resection.
WHO grading
Tumor samples from all patients included in this study were
acquired through open microsurgical resection, and formalin-
fixed paraffin-embedded (FFPE) specimens were used for
analysis. The tumors were classified and staged according to
the current WHO 2016 classification of tumors of the central
nervous system. The neuropathologist was blinded for the
clinical outcome data.
DNA isolation
DNA isolation from surgical tumor specimens was performed
as previously described [3]. In short, representative H&E-
stained FFPE tumor slides were prepared, and tumor regions
with at least 90% tumor cells were microscopically identified.
DNA extraction was performed by microdissection of target
regions on serial slides. Purification of DNA was performed
using standard protocols. DNA quantity was determined using
a NanoDrop system determining the 260/280 nm absorbance
ratio.
TERT promoter mutation analysis
Analysis of TERT mutation status was performed by ampli-
fying the TERT promoter region including the two hotspot
mutations C250T and C228T that are located − 146 bp and
− 124 bp upstream of the TERT gene. We applied standard
PCR protocols and direct capillary sequencing as previously
described [3].
Statistical analysis
Data is given as mean ± standard deviation of the mean if not
indicated otherwise. A comparison of baseline variables be-
tween patient cohorts was performed using the X2 test for
categorical variables, t test for parametric variables, and
Mann-Whitney U-test for nonparametric variables. Survival
function of time was illustrated via the Kaplan-Meier method
(log-rank test). Multivariate analysis was performed using
Cox proportional hazard regression model to estimate p value,
hazard ratio, and 95% confidence interval. Statistical analysis
was performed using a standard software package (SPSS
Statistics version 25, Chicago, IL). Significance level was
set at p < 0.05.
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Results
Patients and clinical data
Nine hundred forty-seven patients with intracranial meningi-
oma WHO grade I treated between 2002 and 2016 were
screened to meet the inclusion criteria. Three hundred
seventy-five patients were excluded due to short follow-up
time, and 156 patients were excluded because only subtotal
tumor resection was achieved. We therefore identified 416
patients with intracranial meningioma WHO grade I who
underwent complete tumor resection (Fig. 1) including 305
women and 121 men with a median age of 57 years (range:
21–89 years). Meningiomas were primarily located at the
skull base (n = 236; 56.7%) and to less extent involved the
cranial convexity (n = 180; 43.3%). Given that all of our
highly selected patients hadWHO grade I tumors and no signs
of residual meningioma after resection, postoperative radio-
therapy was not applied in any of our patients. The postoper-
ative course was unremarkable in most patients.
We retrospectively assigned all 416 patients meeting our
inclusion criteria into two groups based on their past oncolog-
ical history (Table 1), and 46 (11.1%) patients were positive
for tumors other than meningioma. We identified 19 (all fe-
males; 41.3%) out of 46 patients with breast cancer, four
(8.7%) patients with ovarian cancer, three (6.5%) patients with
thyroid cancer, three (6.5%) patients with uterine myoma, and
15 (32.6%) patients with other tumor entities (Table 2). TERT
promoter mutation was not detected in any of the patients with
a positive oncological history. Moreover, patients with and
without positive medical history did not differ in terms of
age, tumor location, or mitotic cell count on neuropathological
meningioma analysis. Of note, predominantly female patients
were positive for a positive oncological history other than
meningioma (p = 0.005), potentially due to the high number
of breast cancer patients.
Outcome
The median follow-up time after meningioma surgery was 58
months for all 416 patients (range: 6–190 months). After com-
plete resection, the median recurrence-free survival (RFS) af-
ter complete resection of meningioma was 56 months in the
entire cohort. While 9 (19.6%) out of 46 patients with a per-
sonal history of tumors other than meningioma developed
tumor recurrence, only 34 (9.2%) out of 370 patients without
such history did so (p = 0.034) (Fig. 2). Six patients suffered
from a tumor progression other than meningioma, and three
patients eventually died of tumor-related complications. No
deaths occurred due to the progress of meningioma.
Multivariate analysis for prognostic factors on recurrence-free
survival
Univariate andmultivariate analysis was performed to identify
prognostic factors of RFS for patients with WHO grade I
meningiomas after complete resection (Table 3). The follow-
ing covariates were included in the statistical models: age, sex,
clinical history of unrelated tumor disease, localization (skull
base vs. convexity), and mitosis count in meningioma sam-
ples. Interestingly, the clinical history of tumors other than
meningioma was among the covariates associated with out-
come (p = 0.004, HR = 3.1, CI = 1.4–6.8) in both uni- and
multivariate analysis, with the strongest association. Male sex
(p = 0.009, HR = 0.4, CI = 0.3–08) and tumor localization at
the cranial convexity (p = 0.039, HR = 2.0, CI = 1.0–3.7) were
also associated with shortened RFS in our cohort.
Discussion
Meningiomas are the most commonly encountered primary
intracranial neoplasms in adults. A considerable number of
meningiomas WHO grade I can be cured by surgery; howev-
er, a considerable percentage reoccurs after complete resec-
tion. Therefore, long-term tumor control remains a significant
challenge in the treatment of benign meningiomas [9]. In the
present study, we aimed to elucidate whether a past medical
history of prior tumors other than meningioma might be an
additional risk factor for recurrence after complete resection of
meningioma WHO grade I [8]. To the best of our knowledge,
we found for the first time that a past medical history of tu-
mors other than meningiomas appears to be strongly correlat-
ed with the risk of meningioma WHO grade I recurrence after
complete resection. Similar findings have been made among
patients with radiosurgically treated vestibular schwannoma
[27]. Of interest, we did not find evidence that our analysisFig. 1 Flowchart of patient selection for inclusion in the study
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might be confounded by other factors such as age, tumor
localization (convexity vs. skull base), or mitotic cell count.
Rather, the MIB index, including various cutoff values for the
prediction of meningioma (WHO grade I) recurrence, is still
highly controversial and therefore not included in the current
WHO classification [10, 18]. In the current study, the neuro-
pathological analysis set the emphasis on the mitotic cell in-
dex within the WHO grade I meningiomas, not considering
the MIB index for proliferation. Also, other molecular and
epigenetic markers in meningioma such as TERT promoter
mutation, loss of histone methylation, as well as complex
methylation signatures have been very recently associated
with early meningioma recurrence and progression [3, 16,
20, 21]. We therefore conducted a TERT promoter status
analysis in our study cohort, hypothesizing that TERT pro-
moter mutation might link the other tumors and meningioma
in our patients. However, TERT promoter mutation was ab-
sent in patients harboring both meningioma and unrelated tu-
mor disease.
We found that most of our meningioma patients with a
positive oncological history had tumors of the female repro-
ductive tract, including breast cancer, ovarian cancer, and
uterine myoma. Individuals with hereditary mutations in
BRCA1 and BRCA2 are predisposed to a higher risk of breast
or ovarian cancer. Lombardi et al. illustrated that the silencing
of BRCA1 by hypermethylation might also play an important
role in meningioma development [14]. Furthermore, a poly-
morphic variation within the BRIP1 is a risk factor for menin-
gioma development and was also identified in breast cancer
patients [2]. On a cautionary note, we did not find evidence of
familial cancer syndromes in our patients. Tumors of the fe-
male reproductive tract as well as meningioma were shown to
express high levels of estrogen and progesterone receptors on
their cell membrane, which makes them both particularly sus-
ceptible to exogenous hormone levels and may explain the
female predominance among meningioma patients [13].
Heightened hormonal levels have also been associated with
the myoma development, and women with myomas were re-
ported at increased risk for meningioma [28]. Genome-wide
screening of potential genetic predispositions, linking the ag-
gressive meningioma phenotype to the other cancers encoun-
tered in our cohort, was outside of our main focus. However,
Table 1 Patient characteristics
Clinical history of unrelated tumor disease Yes No p value
Total 46 (11.1%) 370 (88.9%)
Median FU, months (range) 53 (7–111) 56 (6–190) 0.910
Median age at diagnosis, years (range) 63 (28–83) 57 (21–89) 0.12
Sex
Female 41 (89.1%) 264 (71.4%) 0.005
Male 5 (10.9%) 106 (28.6%)
Localization
Skull base 21 (45.7%) 215 (58.1%) 0.07
Convexity 25 (54.3%) 155 (41.9%)
Mitosis rate, per HPF (range) 0 (0–3) 0 (0–1) 0.25
Recurrence 9 (19.6%) 34 (9.2%) 0.034
Table 2 Tumor entities
Tumor entity N = 46 (%)
Breast cancer 19 (41.3)
Ovarian cancer 4 (8.7)
Leukemia/lymphoma 2 (4.3)
Renal cancer 2 (4.3)
Myoma 2 (4.3)
Lung cancer 1 (2.2)
Prostate cancer 1 (2.2)
Others 15 (32.6)
Fig. 2 Kaplan-Meier estimates of progression-free survival (PFS) strati-
fied according to the presence/absence of tumor disease other than
meningioma
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we believe that our study results will serve as a solid starting
point for pursuing such hypothesis in future studies.
Most of our patients with a positive oncological history had
malignant and rather aggressive neoplasms, which warranted
prior anti-tumor therapy. Systemic chemotherapy and radio-
therapy to the neuroaxis provided in survivors of childhood
cancers have been shown to dramatically increase the risk of
meningioma [6, 12]. In our series, two patients were receiving
CNS axis radiation as a treatment for the malignancy other
than meningioma; the remaining patients had no radiation of
the skull and neck area. In turn, environmental and lifestyle
factors such as tobacco use and excessive alcohol intake are
known to be associated with a variety of cancers we have
encountered, but an association with meningioma could not
be established in prior studies. Although rather controversial,
sex hormones, obesity, hypertension, and diabetes might be
more likely to be associated with risk of meningioma devel-
opment [1, 22, 23]. We did not control for such factors, and
we cannot rule out the possibility that such markers might
have confounded our analysis. Whether positive personal his-
tory for tumors other than meningiomas is a completely inde-
pendent risk factor for meningioma recurrence remains there-
fore to be shown. Other limitations of our study may include
its retrospective design and the rather small number of patients
with a positive oncological history. Given the limited sample
size, we were not able to perform an elaborated subgroup
analysis for outcome among patients with a positive oncolog-
ical history.
In the current study, we demonstrated that male sex might
be associated with significantly shorter RFS. Sex-dependent
differences in the prognosis of meningiomas have yet been
reported with less favorable outcome among male patients
[19]. One possibility is the progesterone-receptor independent
growth of meningiomas in male patients. However, it had
been shown that the progesterone receptor is only expressed
on non-dividing meningioma cells. Thus, further genetic al-
terations that might provide an explanation have yet to be
elucidated [25].
Collectively, our data show that a past medical history pos-
itive for tumors other than meningioma is associated with less
favorable recurrence-free survival in meningioma patients
after complete resection. These results may be useful to guide
personalized patient management during the postoperative
follow-up period, and a closer follow-up might be particularly
recommended in patients with an oncological past medical
history. Further studies may identify systemic genetic alter-
ations or etiological risk factors underlying both meningioma
development and formation of independent tumors.
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